Barbara M. Brooks-Worrell,Ashley H. Tjaden,Sharon L. Edelstein,Brenda Palomino,Kristina M. Utzschneider,Silva Arslanian,Kieren J. Mather,Thomas A. Buchanan,Kristen J. Nadeau,Karen Atkinson,Elena Barengolts,Steven E. Kahn,Jerry P. Palmer,The RISE Consortium,David A. Ehrmann,Karla A. Temple,Abby Rue,Elena Barengolts,Babak Mokhlesi,Eve Van Cauter,Susan Sam,M. Annette Miller,Steven E. Kahn,Karen M. Atkinson,Jerry P. Palmer,Kristina M. Utzschneider,Tsige Gebremedhin,Abigail Kernan-Schloss,Alexandra Kozedub,Brenda K. Montgomery,Emily J. Morse,Kieren J. Mather,Tammy Garrett,Tamara S. Hannon,Amale Lteif,Aniket Patel,Robin Chisholm,Karen Moore,Vivian Pirics,Linda Pratt,Kristen J. Nadeau,Susan Gross,Philip S. Zeitler,Jayne Williams,Melanie Cree-Green,Yesenia Garcia Reyes,Krista Vissat,Silva A. Arslanian,Kathleen Brown,Nancy Guerra,Kristin Porter,Sonia Caprio,Mary Savoye,Bridget Pierpont,Thomas A. Buchanan,Anny H. Xiang,Enrique Trigo,Elizabeth Beale,Ting Chow,Fadi N. Hendee,Namir Katkhouda,Krishan Nayak,Mayra Martinez,Cortney Montgomery,Xinhui Wang,Jun Wu,Sharon L. Edelstein,John M. Lachin,Ashley Hogan Tjaden,Mark T. Tripputi,Santica Marcovina,Jessica Harting,John Albers,Dave Hill,Peter J. Savage,Ellen W. Leschek,

Abstract:The presence of islet autoantibodies and islet reactive T cells (T+) in adults with established type 2 diabetes (T2D) have been shown to identify those patients with more severe β-cell dysfunction. However, at what stage in the progression toward clinical T2D does islet autoimmunity emerge as an important component influencing β-cell dysfunction? In this ancillary study to the Restoring Insulin SEcretion (RISE) Study, we investigated the prevalence of and association with β-cell dysfunction of T+ and autoantibodies to the 65 kDa glutamic acid decarboxylase antigen (GADA) in obese pre-diabetes adults with impaired glucose tolerance (IGT) and recently diagnosed treatment naïve (Ndx) T2D. We further investigated the effect of 12 months of RISE interventions (metformin or liraglutide plus metformin, or with 3 months of insulin glargine followed by 9 months of metformin or placebo) on islet autoimmune reactivity. We observed GADA(+) in 1.6% of NdxT2D and 4.6% of IGT at baseline, and in 1.6% of NdxT2D and 5.3% of IGT at 12 months, but no significant associations between GADA(+) and β-cell function. T(+) was observed in 50% of NdxT2D and 60.4% of IGT at baseline, and in 68.4% of NdxT2D and 83.9% of IGT at 12 months. T(+) NdxT2D were observed to have significantly higher fasting glucose ( p = 0.004), and 2 h glucose ( p = 0.0032), but significantly lower steady state C-peptide (sscpep, p = 0.007) compared to T(−) NdxT2D. T(+) IGT participants demonstrated lower but not significant ( p = 0.025) acute (first phase) C-peptide response to glucose (ACPRg) compared to T(−) IGT. With metformin treatment, T(+) participants were observed to have a significantly lower Hemoglobin A1c (HbA1c, p = 0.002) and fasting C-peptide ( p = 0.002) compared to T(−), whereas T(+) treated with liraglutide + metformin had significantly lower sscpep ( p = 0.010) compared to T(−) participants. In the placebo group, T(+) participants demonstrated significantly lower ACPRg ( p = 0.001) compared to T(−) participants. In summary, T(+) were found in a large percentage of obese pre-diabetes adults with IGT and in recently diagnosed T2D. Moreover, T(+) were significantly correlated with treatment effects and β-cell dysfunction. Our results demonstrate that T(+) are an important component in T2D.

Clinical care advice for monitoring of islet autoantibody positive individuals with presymptomatic type 1 diabetes

Consensus Guidance for Monitoring Individuals With Islet Autoantibody–Positive Pre-Stage 3 Type 1 Diabetes

Recommendations for Screening and Monitoring the Stages of Type 1 Diabetes in the Immune Therapy Era

Data-Driven Phenotyping of Presymptomatic Type 1 Diabetes Using Longitudinal Autoantibody Profiles

Childhood screening for type 1 diabetes comparing automated multiplex Antibody Detection by Agglutination-PCR (ADAP) with single plex islet autoantibody radiobinding assays

Follow-up and monitoring programme in children identified in early-stage type 1 diabetes during screening in the general population of Italy

Clinical Prediction Models Combining Routine Clinical Measures Have High Accuracy in Identifying Youth-Onset Type 2 Diabetes Defined by Maintained Endogenous Insulin Secretion: The SEARCH for Diabetes in Youth Study

Association of the apoptotic markers Apo1/Fas and cCK-18 and the adhesion molecule ICAM-1 with Type 1 diabetes mellitus in children and adolescents

Screening Strategy for Islet Autoantibodies in Diabetes Patients of Different Ages.

Have interventions aimed at assisting general practitioners in facilitating earlier diagnosis of type 1 diabetes in children been successful in preventing acute complications? A systematic review

The Study on the Risk of Other Endocrine Glands Autoimmune Diseases in Patients with Type 1 Diabetes Mellitus

Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes

General population screening for type 1 diabetes using islet autoantibodies at the preschool vaccination visit: a proof-of-concept study (the T1Early study)

1457-P: Challenges in Detecting Immune Checkpoint Inhibitor-Induced Type 1 Diabetes Mellitus by Glucose Monitoring

Early Dysglycemia Is Detectable Using Continuous Glucose Monitoring in Very Young Children at Risk of Type 1 Diabetes

Islet autoantibody frequency in relatives of children with type 1 diabetes who have a type 2 diabetes diagnosis

Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR assay

Clinical prediction models combining routine clinical measures identify participants with youth-onset diabetes who maintain insulin secretion in the range associated with type 2 diabetes: The SEARCH for Diabetes in Youth Study

Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study

Erratum. Consensus Guidance for Monitoring Individuals With Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes. Diabetes Care 2024;47:1276-1298

Autoantibodies against beta cells to predict early insulin requirements in pediatric patients with clinically diagnosed type 2 diabetes